HER2-Low Breast Cancer: Pathological and Clinical LandscapePaolo Tarantino, Giuseppe Curigliano, Fabrice André et al.|Journal of Clinical Oncology|2020Cited by 801
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real lifeStefania Morganti, Giuseppe Curigliano, Paolo Tarantino et al.|Critical Reviews in Oncology/Hematology|2018Cited by 149
Artificial intelligence entering the pathology arena in oncology: current applications and future perspectivesAntonio Marra, Jakob Nikolas Kather, Stefania Morganti et al.|Annals of Oncology|2025Cited by 61
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involutionAmy E. Schade, Karen Cichowski, Naiara Perurena et al.|Nature|2024Cited by 56
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?Stefania Morganti, Carmen Criscitiello, Giampaolo Bianchini et al.|ESMO Open|2022Cited by 11